Nessan Bermingham

Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark.

PreciSense A/S developed and distributed non-invasive blood glucose monitoring systems that allows for frequent and painless measurement of blood glucose for the long term benefit of diabetics. Its products were used to control day-to-day therapy both regarding insulin administration in Type I and other therapies in Type II diabetes in order to prevent late stage complications. PreciSense was founded in 1995 and was headquartered in Horsholm, Denmark.

Khosla Ventures LLC (Khosla Ventures) is a venture capital firm founded in 2004 by Vinod Khosla. The firm is headquartered in Menlo Park, California.

Serentis Ltd. discovered, developed and distributed pharmaceutical products. The company was founded by Tim Sharpington, Alan Rothaul, and Andy Baxter in 2006 and was headquartered in London, the United Kingdom.

Renovo Services LLC provided vehicle transition services for financial services professionals in North America and Puerto Rico. The company was headquartered in Nashville, TN.

Bio Equity Capital LLC (Bio Equity Capital) is a private equity firm founded in 2009 by Nessan Bermingham and Joseph Siletto. The firm is headquartered in Boston, Massachusetts.

F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.

Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada.

F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.

Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Part of Sino Biopharmaceutical Ltd., F-Star Delta Ltd. develops antibody products to improve the treatment of serious diseases. The private company is based in Cambridge, UK and was founded in 2016.

F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom.

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

EveryONE Medicines, Inc. delivers individualized precision therapeutics customized to the unique pathogenic genetic mutation of patients. EveryONE Medicines is based in Boston, MA. The company's goal is to provide quality of life to patients by slowing or even halting their disease. The company was founded by Julia Vitarello and Keith Flanagan. The CEO is Nessan Bermingham.

Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then.

Liberate Bio, Inc. develops novel genetic medicines. The company is based in Boston, MA. The company was founded by Michael Mitchell, Nessan Bermingham, Stephen Scully, Theresa M. Reineke. The CEO is Shawn Davis.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.